MCB 3837

Drug Profile

MCB 3837

Alternative Names: MCB-3681; MCB-3837; oxaquin

Latest Information Update: 25 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Morphochem AG
  • Developer Biovertis AG; Evotec AG; Morphochem AG
  • Class Antibacterials; Oxazolidinones; Quinolones
  • Mechanism of Action DNA topoisomerase inhibitors; Enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Bacterial infections
  • Discontinued Nosocomial infections

Most Recent Events

  • 25 Jul 2016 MCB 3837 receives Qualified Infectious Disease Product status for Clostridium infections in USA
  • 25 Jul 2016 MCB 3837 receives Fast track status from the US FDA for Clostridium infections
  • 22 Jun 2016 US FDA approves IND application for MB 3837 in Bacterial infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top